热门资讯> 正文

Reviva Pharmaceuticals GAAP每股收益为-0.06美元

2025-11-14 05:59

Reviva Pharmaceuticals press release (RVPH): Q3 GAAP EPS of -$0.06.
As of September 30, 2025, the Company’s cash and cash equivalents totaled approximately $13.2 million compared to approximately $13.5 million as of December 31, 2024.

More on Reviva Pharmaceuticals

Reviva Pharmaceuticals announces pricing of $9M public offering
Reviva Pharmaceuticals announces proposed public offering
Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals
Historical earnings data for Reviva Pharmaceuticals
Financial information for Reviva Pharmaceuticals

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。